Table 4 Upper respiratory tract and other characteristics before initiation of anti-IL5/IL5R or anti-IgE treatment. The time of use describes mean time of use of biological therapy in months
From: A comparison of biologicals in the treatment of adults with severe asthma – real-life experiences
| Characteristics | Anti-IL5/IL5R | Anti-IgE |
|---|---|---|
| Reslizumab, Mepolizumab, Benralizumab, n = 38 | Omalizumab, n = 17 | |
| Asthma (number, (%)) | 38 (100) | 17 (100) |
| Nasal polyposis as only indication for biological therapy (number, (%)) | 3 (8) | 0 (0) |
| Time of use (months) a | 12.4 (1–29. SD 7.6) | 43.8 (5–109. SD 35.6) |
| Age at analysis (years) | 54.2 (25–72. SD 10.8) | 47.6 (28–76. SD 11.5) |
| Women (number, (%)) | 18 (47) | 12 (71) |
| BMIb (kg/m2) | 28.1 (16.9–38.8. SD 4.8) | 27.6 (23–35. SD 3.3) |
| Use of intranasal corticosteroids (number, (%)) | 34 (89) | 14 (82) |
| Use of oral antihistamine (number, (%)) | 13 (34) | 8 (47) |
| Use of montelukast (number, (%)) | 27 (71) | 9 (53) |
| Positive skin prick test or allergen specific serum IgE (number, (%)) | 16 (42) | 17 (100) |
| Smokers (number, (%)) | 1 (3) | 0 (0) |
| Ex-smokersc (number, (%)) | 9 (24) | 2 (12) |
| Nasal polyposis (number, (%)) | 29 (76) | 11 (65) |
| Chronic rhinosinusitis (CRSwNP or CRSsNP) (number, (%)) | 34 (89) | 15 (88) |
| ASA intolerance (number, (%)) | 9 (24) | 3 (18) |
| Osteoporosis (number, (%)) | 12 (32) | 4 (24) |
| Blood eosinophil count (E9/l) | 0.48 (0.00–1.84. SD 0.38) | 0.50 (0.01–1.21. SD 0.42) |